Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL. (2021)

• Record Type: Journal Article
• Authors: Tabbara, Nadeem; Gaut, Daria; Oliai, Caspian; Lewis, Tara; de Vos, Sven
• Is Part Of: Leukemia research reports. Volume 16(2021)
• Publication Date: 2021
• Subjects: Diffuse large B-cell lymphoma -- Tafasitamab -- Chimeric antigen receptor T-cell therapy -- CD19; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2021.100260
• Languages: English
• ISSNs: 2213-0489

Abstract

Highlights: Disease progression following anti-CD19 monoclonal antibody Tafasitamab treatment should not preclude subsequent anti-CD19 CART-cell therapy. Previous studies have demonstrated sequential anti-CD19 to be effective. Larger studies among R/R DLBCL patients across anti-CD19 modalities are needed to guide sequencing of therapies following initial anti-CD19 therapy. Abstract: Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L -MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival of 16 months in R/R DLBCL patients ineligible for autologous stem cell transplantation. Despite recent advances in anti-CD19 therapy, no clinical evidence exists to direct the sequencing of CAR T cell therapy following relapse after prior anti-CD19 therapy. We present the first published case of TAFA/LEN treatment followed by CAR T therapy with sustained remission. Disease progression following treatment with Tafasitamab may not preclude patients from CAR T cell therapy.